159 related articles for article (PubMed ID: 12894231)
1. Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer.
Maliekal TT; Antony ML; Nair A; Paulmurugan R; Karunagaran D
Oncogene; 2003 Jul; 22(31):4889-97. PubMed ID: 12894231
[TBL] [Abstract][Full Text] [Related]
2. Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.
Wang D; Kanuma T; Mizunuma H; Takama F; Ibuki Y; Wake N; Mogi A; Shitara Y; Takenoshita S
Cancer Res; 2000 Aug; 60(16):4507-12. PubMed ID: 10969799
[TBL] [Abstract][Full Text] [Related]
3. A novel SMAD4 gene mutation in seminoma germ cell tumors.
Bouras M; Tabone E; Bertholon J; Sommer P; Bouvier R; Droz JP; Benahmed M
Cancer Res; 2000 Feb; 60(4):922-8. PubMed ID: 10706106
[TBL] [Abstract][Full Text] [Related]
4. Smad4 deficiency in cervical carcinoma cells.
Baldus SE; Schwarz E; Lohrey C; Zapatka M; Landsberg S; Hahn SA; Schmidt D; Dienes HP; Schmiegel WH; Schwarte-Waldhoff I
Oncogene; 2005 Jan; 24(5):810-9. PubMed ID: 15531914
[TBL] [Abstract][Full Text] [Related]
5. SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway.
Woodford-Richens KL; Rowan AJ; Gorman P; Halford S; Bicknell DC; Wasan HS; Roylance RR; Bodmer WF; Tomlinson IP
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9719-23. PubMed ID: 11481457
[TBL] [Abstract][Full Text] [Related]
6. Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.
Kuang C; Chen Y
Oncogene; 2004 Feb; 23(5):1021-9. PubMed ID: 14647410
[TBL] [Abstract][Full Text] [Related]
7. Mutational analysis of TGF-beta type II receptor, Smad2, Smad3, Smad4, Smad6 and Smad7 genes in colorectal cancer.
Fukushima T; Mashiko M; Takita K; Otake T; Endo Y; Sekikawa K; Takenoshita S
J Exp Clin Cancer Res; 2003 Jun; 22(2):315-20. PubMed ID: 12866583
[TBL] [Abstract][Full Text] [Related]
8. Smad expression in human atherosclerotic lesions: evidence for impaired TGF-beta/Smad signaling in smooth muscle cells of fibrofatty lesions.
Kalinina N; Agrotis A; Antropova Y; Ilyinskaya O; Smirnov V; Tararak E; Bobik A
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1391-6. PubMed ID: 15166010
[TBL] [Abstract][Full Text] [Related]
9. Status of the DPC4 tumor suppressor gene in sporadic colon adenocarcinoma of Croatian patients: identification of a novel somatic mutation.
Popović Hadzija M; Radosevic S; Kovacević D; Lukac J; Hadzija M; Spaventi R; Pavelić K; Kapitanović S
Mutat Res; 2004 Apr; 548(1-2):61-73. PubMed ID: 15063137
[TBL] [Abstract][Full Text] [Related]
10. A complex pattern of mutations and abnormal splicing of Smad4 is present in thyroid tumours.
Lazzereschi D; Nardi F; Turco A; Ottini L; D'Amico C; Mariani-Costantini R; Gulino A; Coppa A
Oncogene; 2005 Aug; 24(34):5344-54. PubMed ID: 15940269
[TBL] [Abstract][Full Text] [Related]
11. The L3 loop and C-terminal phosphorylation jointly define Smad protein trimerization.
Chacko BM; Qin B; Correia JJ; Lam SS; de Caestecker MP; Lin K
Nat Struct Biol; 2001 Mar; 8(3):248-53. PubMed ID: 11224571
[TBL] [Abstract][Full Text] [Related]
12. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
13. Sequential gonadotropin treatment of immature mice leads to amplification of transforming growth factor beta action, via upregulation of receptor-type 1, Smad 2 and 4, and downregulation of Smad 6.
Guéripel X; Benahmed M; Gougeon A
Biol Reprod; 2004 Mar; 70(3):640-8. PubMed ID: 14585817
[TBL] [Abstract][Full Text] [Related]
14. Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-beta.
Jazag A; Ijichi H; Kanai F; Imamura T; Guleng B; Ohta M; Imamura J; Tanaka Y; Tateishi K; Ikenoue T; Kawakami T; Arakawa Y; Miyagishi M; Taira K; Kawabe T; Omata M
Oncogene; 2005 Jan; 24(4):662-71. PubMed ID: 15592526
[TBL] [Abstract][Full Text] [Related]
15. Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines.
Tian F; Byfield SD; Parks WT; Stuelten CH; Nemani D; Zhang YE; Roberts AB
Cancer Res; 2004 Jul; 64(13):4523-30. PubMed ID: 15231662
[TBL] [Abstract][Full Text] [Related]
16. Frequency of Smad gene mutations in human cancers.
Riggins GJ; Kinzler KW; Vogelstein B; Thiagalingam S
Cancer Res; 1997 Jul; 57(13):2578-80. PubMed ID: 9205057
[TBL] [Abstract][Full Text] [Related]
17. Modeling and analysis of MH1 domain of Smads and their interaction with promoter DNA sequence motif.
Makkar P; Metpally RP; Sangadala S; Reddy BV
J Mol Graph Model; 2009 Apr; 27(7):803-12. PubMed ID: 19157940
[TBL] [Abstract][Full Text] [Related]
18. DCC and SMAD4 alterations in human colorectal and pancreatic tumor dissemination.
Tarafa G; Villanueva A; Farré L; Rodríguez J; Musulén E; Reyes G; Seminago R; Olmedo E; Paules AB; Peinado MA; Bachs O; Capellá G
Oncogene; 2000 Jan; 19(4):546-55. PubMed ID: 10698524
[TBL] [Abstract][Full Text] [Related]
19. [Alterations in DPC4 gene in pancreatic cancers].
Gu L; Chen J; Cui Q
Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):293-5. PubMed ID: 11783110
[TBL] [Abstract][Full Text] [Related]
20. Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses.
Levy L; Hill CS
Mol Cell Biol; 2005 Sep; 25(18):8108-25. PubMed ID: 16135802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
